Fluvastatin sodium ER tablets had a market value of approximately $10 million for the 12 months ended May 2021, although actual generic market values are expected to be lower, according to IQVIA.
Desipramine hydrochloride tablets had a market value of roughly $7 million, while erlotinib tablets had a market value of $37 million, for the 12 months ended March 2021, according to IQVIA.